Caplin Point Laboratories Ltd
NSE:CAPLIPOINT

Watchlist Manager
Caplin Point Laboratories Ltd Logo
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Watchlist
Price: 2 040.85 INR Market Closed
Market Cap: 155.1B INR

CAPLIPOINT's latest stock split occurred on Oct 19, 2016

The company executed a 5-for-1 stock split, meaning that for every share held, investors received 5 new shares.

Before the split, CAPLIPOINT traded at 1455 per share. Afterward, the share price was about 284.74.

The adjusted shares began trading on Oct 19, 2016. This was the only stock split in CAPLIPOINT's history.

Last Splits:
Oct 19, 2016
5-for-1
Pre-Split Price
282.89 1 455
Post-Split Price
284.74
Before
After
Last Splits:
Oct 19, 2016
5-for-1

Caplin Point Laboratories Ltd
Stock Splits History

CAPLIPOINT Stock Splits Timeline
Oct 19, 2016
Oct 19, 2016
Split 5-for-1
x5
Pre-Split Price
282.89 1 455
Post-Split Price
284.74
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 1, 2025
I
Icon Energy Corp
NASDAQ:ICON
1-for-40
/40
0.0478 1.912 USD 1.79 1.79 USD
Apr 1, 2025
V
Vortex Energy Corp
CNSX:VRTX
1-for-10
/10
0.075 0.075 CAD 0.11 0.11 CAD
Apr 1, 2025
R
Resource Centrix Holdings Inc
CNSX:RECE
10-for-1
x10
2.4 0.24 CAD 0.24 0.24 CAD
Apr 1, 2025
V
Vortex Energy Corp
OTC:VTECF
1-for-10
/10
0.05 0.5 USD 0.0378 0.0378 USD
Mar 31, 2025
Utime Ltd
NASDAQ:WTO
1-for-10
/10
0.151 1.51 USD 1.58 1.58 USD
Load More

Caplin Point Laboratories Ltd
Glance View

Economic Moat
Wide
Market Cap
155.1B INR
Industry
Pharmaceuticals

Nestled in the bustling business corridors of Chennai, Caplin Point Laboratories Ltd. emerged quietly yet resolutely from its humble origins in 1990. With foresight and strategic maneuvering, the company embarked on a global journey, primarily serving markets across the African, Latin American, and Southeast Asian regions. The firm specializes in a wide array of pharmaceutical products, encompassing everything from injectables and ophthalmics to oral solids and liquids. By focusing on markets that were often overlooked by larger pharmaceutical giants, Caplin Point carved out a niche that allowed it to flourish with minimal competition. The company's business model hinges on leveraging cost-effective manufacturing paired with a deep understanding of diverse regulatory environments, deftly navigating these to establish a loyal customer base amidst underrepresented geographies. The revenue streams of Caplin Point Laboratories are primarily fueled by its ability to adapt product lines to meet the specific needs of each market it serves. This adaptability, combined with a robust distribution network, facilitates the swift movement of goods—ensuring prompt delivery to consumers who rely on its products for basic health needs. Through strategic partnerships and continual investment in research and development, Caplin Point enhances its capacity for innovation, allowing it to advance the quality and range of its pharmaceutical offerings. Furthermore, the company has steadily expanded into regulated markets with its sights set on injectables and has plans for further diversification. This strategic orientation underscores its ambition to transition from a regional powerhouse to a formidable player on the broader global stage.

CAPLIPOINT Intrinsic Value
1 187.11 INR
Overvaluation 42%
Intrinsic Value
Price
Back to Top